Kymera Therapeutics (NASDAQ:KYMR) versus Inhibikase Therapeutics (NYSE:IKT) Head to Head Comparison

Kymera Therapeutics (NASDAQ:KYMR) and Inhibikase Therapeutics (NYSE:IKT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Kymera Therapeutics and Inhibikase Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	0	6	7	0	2.54
Inhibikase Therapeutics	0	0	1	0	3.00

Kymera Therapeutics presently has a consensus price target of $41.20, indicating a potential upside of 12.69%. Inhibikase Therapeutics has a consensus price target of $27.00, indicating a potential upside of 1,608.86%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Kymera Therapeutics.

Institutional and Insider Ownership

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 16.7% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 20.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Kymera Therapeutics and Inhibikase Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$78.59 million	28.31	-$146.96 million	($2.52)	-14.45
Inhibikase Therapeutics	$260,000.00	39.13	-$19.03 million	($3.56)	-0.44

Inhibikase Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Kymera Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Profitability

This table compares Kymera Therapeutics and Inhibikase Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-187.00%	-34.83%	-25.30%
Inhibikase Therapeutics	-5,886.15%	-107.54%	-91.82%

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.